Quest Diagnostics Total Liabilities and Share Holders Equity 2010-2024 | DGX
Quest Diagnostics total liabilities and share holders equity from 2010 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
- Quest Diagnostics total liabilities and share holders equity for the quarter ending September 30, 2024 was $16.095B, a 19.38% increase year-over-year.
- Quest Diagnostics total liabilities and share holders equity for 2023 was $14.022B, a 9.23% increase from 2022.
- Quest Diagnostics total liabilities and share holders equity for 2022 was $12.837B, a 5.69% decline from 2021.
- Quest Diagnostics total liabilities and share holders equity for 2021 was $13.611B, a 2.96% decline from 2020.
Quest Diagnostics Annual Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2023 |
$14,022 |
| 2022 |
$12,837 |
| 2021 |
$13,611 |
| 2020 |
$14,026 |
| 2019 |
$12,843 |
| 2018 |
$11,003 |
| 2017 |
$10,503 |
| 2016 |
$10,100 |
| 2015 |
$9,962 |
| 2014 |
$9,857 |
| 2013 |
$8,948 |
| 2012 |
$9,284 |
| 2011 |
$9,313 |
| 2010 |
$8,528 |
| 2009 |
$8,564 |
Quest Diagnostics Quarterly Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2024-09-30 |
$16,095 |
| 2024-06-30 |
$13,881 |
| 2024-03-31 |
$13,954 |
| 2023-12-31 |
$14,022 |
| 2023-09-30 |
$13,482 |
| 2023-06-30 |
$13,425 |
| 2023-03-31 |
$12,794 |
| 2022-12-31 |
$12,837 |
| 2022-09-30 |
$13,223 |
| 2022-06-30 |
$13,312 |
| 2022-03-31 |
$13,442 |
| 2021-12-31 |
$13,611 |
| 2021-09-30 |
$13,572 |
| 2021-06-30 |
$12,861 |
| 2021-03-31 |
$13,931 |
| 2020-12-31 |
$14,026 |
| 2020-09-30 |
$14,143 |
| 2020-06-30 |
$12,990 |
| 2020-03-31 |
$12,049 |
| 2019-12-31 |
$12,843 |
| 2019-09-30 |
$12,019 |
| 2019-06-30 |
$11,760 |
| 2019-03-31 |
$11,937 |
| 2018-12-31 |
$11,003 |
| 2018-09-30 |
$10,986 |
| 2018-06-30 |
$10,747 |
| 2018-03-31 |
$10,695 |
| 2017-12-31 |
$10,503 |
| 2017-09-30 |
$10,439 |
| 2017-06-30 |
$10,171 |
| 2017-03-31 |
$10,109 |
| 2016-12-31 |
$10,100 |
| 2016-09-30 |
$10,173 |
| 2016-06-30 |
$10,109 |
| 2016-03-31 |
$10,097 |
| 2015-12-31 |
$9,962 |
| 2015-09-30 |
$10,074 |
| 2015-06-30 |
$9,720 |
| 2015-03-31 |
$10,613 |
| 2014-12-31 |
$9,857 |
| 2014-09-30 |
$9,801 |
| 2014-06-30 |
$9,757 |
| 2014-03-31 |
$9,550 |
| 2013-12-31 |
$8,948 |
| 2013-09-30 |
$8,928 |
| 2013-06-30 |
$9,036 |
| 2013-03-31 |
$9,306 |
| 2012-12-31 |
$9,284 |
| 2012-09-30 |
$9,319 |
| 2012-06-30 |
$9,393 |
| 2012-03-31 |
$9,451 |
| 2011-12-31 |
$9,313 |
| 2011-09-30 |
$9,326 |
| 2011-06-30 |
$9,431 |
| 2011-03-31 |
$9,225 |
| 2010-12-31 |
$8,528 |
| 2010-09-30 |
$8,459 |
| 2010-06-30 |
$8,482 |
| 2010-03-31 |
$8,516 |
| 2009-12-31 |
$8,564 |
| 2009-09-30 |
$8,366 |
| 2009-06-30 |
$8,211 |
| 2009-03-31 |
$8,347 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$17.788B |
$9.252B |
|
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
|
